Regen BioPharma Identifies Immune Checkpoint as Potential Lupus Treatment
Regen BioPharma has identified small molecules that activate NR2F6, an immune checkpoint recently identified by the company. This is the first step in a series of initiatives to develop small molecules the biotech will use as the basis to create an oral drug with potent anti-inflammatory properties, or a checkpoint inhibitor pill.